BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35229992)

  • 1. A sandwich ELISA kit reveals marked elevation of titin N-terminal fragment levels in the urine of mdx mice.
    Shirakawa T; Ikushima A; Maruyama N; Nambu Y; Awano H; Osawa K; Nirasawa K; Negishi Y; Nishio H; Fukushima S; Matsuo M
    Animal Model Exp Med; 2022 Feb; 5(1):48-55. PubMed ID: 35229992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.
    Robertson AS; Majchrzak MJ; Smith CM; Gagnon RC; Devidze N; Banks GB; Little SC; Nabbie F; Bounous DI; DiPiero J; Jacobsen LK; Bristow LJ; Ahlijanian MK; Stimpson SA
    Neuromuscul Disord; 2017 Jul; 27(7):635-645. PubMed ID: 28554556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine titin as a novel biomarker for Duchenne muscular dystrophy.
    Ishii MN; Nakashima M; Kamiguchi H; Zach N; Kuboki R; Baba R; Hirakawa T; Suzuki K; Quinton M
    Neuromuscul Disord; 2023 Apr; 33(4):302-308. PubMed ID: 36871413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients.
    Awano H; Matsumoto M; Nagai M; Shirakawa T; Maruyama N; Iijima K; Nabeshima YI; Matsuo M
    Clin Chim Acta; 2018 Jan; 476():111-116. PubMed ID: 29175173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
    Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receiver operating curve analyses of urinary titin of healthy 3-y-old children may be a noninvasive screening method for Duchenne muscular dystrophy.
    Matsuo M; Shirakawa T; Awano H; Nishio H
    Clin Chim Acta; 2018 Nov; 486():110-114. PubMed ID: 30053403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine.
    Maruyama N; Asai T; Abe C; Inada A; Kawauchi T; Miyashita K; Maeda M; Matsuo M; Nabeshima YI
    Sci Rep; 2016 Dec; 6():39375. PubMed ID: 27991570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titin fragment in urine: A noninvasive biomarker of muscle degradation.
    Matsuo M; Awano H; Maruyama N; Nishio H
    Adv Clin Chem; 2019; 90():1-23. PubMed ID: 31122607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary titin as a biomarker in Fukuyama congenital muscular dystrophy.
    Sato T; Awano H; Ishiguro K; Shichiji M; Murakami T; Shirakawa T; Matsuo M; Nagata S; Ishigaki K
    Neuromuscul Disord; 2021 Mar; 31(3):194-197. PubMed ID: 33563515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
    Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
    Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
    Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
    Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy.
    Boehler JF; Brown KJ; Ricotti V; Morris CA
    Skelet Muscle; 2024 Jan; 14(1):2. PubMed ID: 38229112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice.
    Sacco A; Mourkioti F; Tran R; Choi J; Llewellyn M; Kraft P; Shkreli M; Delp S; Pomerantz JH; Artandi SE; Blau HM
    Cell; 2010 Dec; 143(7):1059-71. PubMed ID: 21145579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
    Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
    Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.
    Crowe KE; Shao G; Flanigan KM; Martin PT
    J Neuromuscul Dis; 2016 May; 3(2):247-260. PubMed ID: 27854211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.